Idorsia to call for a bondholder meeting
Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor
Smart tools for smart investors can be found in our Tools section
Company news (International)
Idorsia to call for a bondholder meeting
Idorsia provides update on the exclusive negotiations for the global rights to aprocitentan
Idorsia enters into exclusive negotiations for global rights to aprocitentan
Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions
Idorsia announces financial results for the first nine months of 2024
New data on aprocitentan to be presented at the ASN Kidney Week 2024
Idorsia announces financial results for the first half 2024
Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call
Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension
Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds
Higher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds
Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ category
Idorsia holds its Annual General Meeting of Shareholders
New data with daridorexant to be presented at SLEEP 2024
Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024
Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders
Idorsia announces changes to Idorsia Executive Committee and Board of Directors
Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor
Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value
Bondholders approve amended terms of the 2024 convertible bonds
Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond
The information service offers company-relevant news from leading newswire services in a compact form for a quick overview. When the detailed view is called up, further information can be accessed if required. The navigation elements in previewer mode allow you to quickly switch to the most frequently visited tool sections. From there, you can access further areas that can be used for your own research and analysis. Tip: The information platform now includes more than 50 mini-apps developed in-house.
Further information
The information presented in this section is secondary publications. The content corresponds to the source information. You can find information on the author of the news item in the detailed information of a publication. News relating to listed companies may have been created due to regulatory publication obligations, due to regular public relations work for PR or marketing reasons or by third parties against the background of investor information.
The combination of information and graphic elements contributes significantly to visual orientation and navigation through complex issues. This makes it easier to grasp, contextualize and process key content. Images, logos and other or comparable graphic and textual elements used on the information portal are used for visual navigation, are part of the original message or have illustrative purposes. All rights to these elements are held by the respective owners of the trademark or image rights. They are used without intent to infringe copyright or intellectual property rights. Image material provided via the distribution networks is treated as part of the original message and processed accordingly.
If you believe that copyright or intellectual property rights have been infringed by the presentation, please contact us immediately to clarify your concerns.